Pituitary function during severe and life-threatening illnesses

Pituitary

Volumn 8, Issue 3-4, 2005, Pages 213-217

  Gauna, C ^a   van den Berghe, G H ^b   van der Lely, A J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Acute disease; Chronic disease; Critical illness; Endocrine system; Energy metabolism; Humans; Physiology; Physiopathology; Stress

Indexed keywords

ADENOHYPOPHYSIS HORMONE; ALPHA INTERMEDIN; CORTICOTROPIN; CYTOKINE; GROWTH HORMONE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 12; PROLACTIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; THYROID HORMONE; THYROTROPIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ADENOHYPOPHYSIS HYPOFUNCTION; ARTICLE; CATABOLISM; CORTICOTROPIN BLOOD LEVEL; CRITICAL ILLNESS; DISEASE SEVERITY; GROWTH HORMONE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; IMMUNE SYSTEM; IMMUNOREGULATION; INSULIN BLOOD LEVEL; INSULIN TREATMENT; NEUROENDOCRINE DISEASE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; PULSATILE HORMONE RELEASE; STRESS; THYROID HORMONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL;

BRAIN INJURIES; CRITICAL ILLNESS; CYTOKINES; ENDOCRINE SYSTEM; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNE SYSTEM; PITUITARY GLAND;

EID: 33645379134     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-006-6043-3     Document Type: Article

References (44)

1. Bondanelli M, Ambrosio MR, Zatelli MC, De Marinis L, et al. Hypopituitarism After Traumatic Brain Injury. Eur J Endocrinol 2005;152:679-691.
2. Agha A, Thornton E, O'Kelly P, Tormey W, et al. Posterior Pituitary Dysfunction After Traumatic Brain Injury. J Clin Endocrinol Metab 2004;89:5987-5992.
3. Aimaretti G, Ambrosio MR, Di Somma C, Fusco A, et al. Traumatic Brain Injury and Subarachnoid Haemorrhage Are Conditions at High Risk for Hypopituitarism: Screening Study at 3 Months After the Brain Injury. Clin Endocrinol (Oxf) 2004;61:320-326.
4. Borg J, Holm L, Cassidy JD, Peloso PM, et al. Diagnostic Procedures in Mild Traumatic Brain Injury: Results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med 2004;61-75.
5. Dimopoulou I, Tsagarakis S, Theodorakopoulou M, Douka E, et al. Endocrine Abnormalities in Critical Care Patients With Moderate-to-Severe Head Trauma: Incidence, Pattern and Predisposing Factors. Intensive Care Med 2004;30:1051-1057.
6. Van den Berghe GH, de Zegher F. Anterior Pituitary Function During Critical Illness and Dopamine Treatment. Crit Care Med 1996;24:1580-1590.
7. Van den Berghe GH, de Zegher F, Baxter RC, Veldhuis JD, et al. Neuroendocrinology of Prolonged Critical Illness: Effects of Exogenous Thyrotropin-Releasing Hormone and Its Combination With Growth Hormone Secretagogues. J Clin Endocrinol Metab 1998;83:309-319.
8. Van den Berghe GH. Dynamic Neuroendocrine Responses to Critical Illness. Front Neuroendocrinol 2002;23:370-391.
9. Van den Berghe GH. Neuroendocrine Pathobiology of Chronic Critical Illness. Crit Care Clin 2002;18:509-528.
10. Van den Berghe GH. Acute and Prolonged Critical Illness Are Two Distinct Neuroendocrine Paradigms. Verh K Acad Geneeskd Belg 1998;60:487-518.
11. Van den Berghe GH. Endocrine Evaluation of Patients With Critical Illness. Endocrinol Metab Clin North Am 2003;32:385-410.
12. Weekers F, Giulietti AP, Michalaki M, Coopmans W, et al. Metabolic, Endocrine, and Immune Effects of Stress Hyperglycemia in a Rabbit Model of Prolonged Critical Illness. Endocrinology 2003;144:5329-5338.
13. Weekers F, Michalaki M, Coopmans W, Van Herck E. et al. Endocrine and Metabolic Effects of Growth Hormone (GH) Compared With GH-Releasing Peptide, Thyrotropin-Releasing Hormone, and Insulin Infusion in a Rabbit Model of Prolonged Critical Illness. Endocrinology 2004;145:205-213.
14. Vanhorebeek I, Van den BG. Hormonal and Metabolic Strategies to Attenuate Catabolism in Critically Ill Patients. Curr Opin Pharmacol 2004;4:621-628.
15. Van den Berghe GH. Role of Intravenous Insulin Therapy in Critically Ill Patients. Endocr Pract 2004;10(Suppl 2):17-20.:17-20.
16. Van den Berghe GH, Wouters P, Weekers F, Verwaest C, et al. Intensive Insulin Therapy in the Critically Ill Patients. N Engl J Med 2001;345:1359-1367.
17. Van den Berghe GH. Insulin Therapy for the Critically Ill Patient. Clin Cornerstone 2003;5:56-63.
18. Van den Berghe GH, Wouters PJ, Bouillon R, Weekers F, et al. Outcome Benefit of Intensive Insulin Therapy in the Critically Ill: Insulin Dose Versus Glycemic Control. Crit Care Med 2003;31:359-366.
19. Gardelis JG, Hatzis TD, Stamogiannou LN, Dona AA, et al. Activity of the Growth Hormone/Insulin-Like Growth Factor-I Axis in Critically Ill Children. J Pediatr Endocrinol Metab 2005;18:363-372.
20. Cogo PE, Carnielli VP, Rosso F, Cesarone A, et al. Protein Turnover, Lipolysis, and Endogenous Hormonal Secretion in Critically Ill Children. Crit Care Med 2002;30:65-70.
21. Balcells J, Moreno A, Audi L, Roqueta J, et al. Growth Hormone/ Insulin-Like Growth Factors Axis in Children Undergoing Cardiac Surgery. Crit Care Med 2001;29:1234-1238.
22. Baxter RC. Changes in the IGF-IGFBP Axis in Critical Illness. Best Pract Res Clin Endocrinol Metab 2001;15:421-434.
23. Kavelaars A, Cobelens PM, Teunis MA, Heijnen CJ. Changes in Innate and Acquired Immune Responses in Mice With Targeted Deletion of the Dopamine Transporter Gene. J Neuroimmunol 2005;161:162-168.
24. Angeli A, Minetto M, Dovio A, Paccotti P. The Overtraining Syndrome in Athletes: A Stress-Related Disorder. J Endocrinol Invest 2004;27:603-612.
25. van Winsen LM, Muris DF, Polman CH, Dijkstra CD, et al. Sensitivity to Glucocorticoids Is Decreased in Relapsing Remitting Multiple Sclerosis. J Clin Endocrinol Metab 2005;90:734-740.
26. Turrin NP, Rivest S. Unraveling the Molecular Details Involved in the Intimate Link Between the Immune and Neuroendocrine Systems. Exp Biol Med (Maywood) 2004;229:996-1006.
27. Boelen A, Kwakkel J, Platvoet-ter Schiphorst M, Mentrup B, et al. Interleukin-18, a Proinflammatory Cytokine, Contributes to the Pathogenesis of Non-Thyroidal Illness Mainly Via the Central Part of the Hypothalamus-Pituitary-Thyroid Axis. Eur J Endocrinol 2004;151:497-502.
28. Brand JM, Frohn C, Cziupka K, Brockmann C, et al. Prolactin Triggers Pro-Inflammatory Immune Responses in Peripheral Immune Cells. Eur Cytokine Netw 2004;15:99-104.
29. Talhouk RS, Saade NE, Mouneimne G, Masaad CA, et al. Growth Hormone Releasing Hormone Reverses Endotoxin-Induced Localized Inflammatory Hyperalgesia Without Reducing the Upregulated Cytokines, Nerve Growth Factor and Gelatinase Activity. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:625-631.
30. Toni R, Malaguti A, Castorina S, Roti E, et al. New Paradigms in Neuroendocrinology: Relationships Between Obesity, Systemic Inflammation and the Neuroendocrine System. J Endocrinol Invest 2004;27:182-186.
31. Eskandari F, Webster JI, Sternberg EM. Neural Immune Pathways and Their Connection to Inflammatory Diseases. Arthritis Res Ther 2003;5:251-265.
32. Kariagina A, Romanenko D, Ren SG, Chesnokova V. Hypothalamic-Pituitary Cytokine Network. Endocrinology 2004;145:104-112.
33. Anisman H, Baines MG, Berczi I, Bernstein CN, et al. Neuroimmune Mechanisms in Health and Disease: 2. Disease. CMAJ 1996;155:1075-1082.
34. Foster SC, Daniels C, Bourdette DN, Bebo BF Jr., Dysregulation of the Hypothalamic-Pituitary-Gonadal Axis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. J Neuroimmunol 2003;140:78-87.
35. Straub RH, Pongratz G, Scholmerich J, Kees F, et al. Long-Term Anti-Tumor Necrosis Factor Antibody Therapy in Rheumatoid Arthritis Patients Sensitizes the Pituitary Gland and Favors Adrenal Androgen Secretion. Arthritis Rheum 2003;48:1504-1512.
36. Xiao E, Xia-Zhang L, Vulliemoz NR, Ferin M, et al. Agouti-Related Protein Stimulates the Hypothalamic-Pituitary-Adrenal (HPA) Axis and Enhances the HPA Response to Interleukin-1 in the Primate. Endocrinology 2003;144:1736-1741.
37. Francis K, Lewis BM, Akatsu H, Monk PN, et al. Complement C3a Receptors in the Pituitary Gland: A Novel Pathway by Which an Innate Immune Molecule Releases Hormones Involved in the Control of Inflammation. FASEB J 2003;17:2266-2268.
38. Berczi I. The Role of the Growth and Lactogenic Hormone Family in Immune Function. Neuroimmunomodulation 1994;1:201-216.
39. Corbacho AM, Macotela Y, Nava G, Eiserich JP, et al. Cytokine Induction of Prolactin Receptors Mediates Prolactin Inhibition of Nitric Oxide Synthesis in Pulmonary Fibroblasts. FEBS Lett 2003;544:171-175.
40. Jorgensen C, Sany J. Modulation of the Immune Response by the Neuro-Endocrine Axis in Rheumatoid Arthritis. Clin Exp Rheumatol 1994;12:435-441.
41. Oberbeck R, Schmitz D, Wilsenack K, Schuler M, et al. Prolactin Modulates Survival and Cellular Immune Functions in Septic Mice. J Surg Res 2003;113:248-256.
42. Sakane T, Suzuki N. Neuro-Endocrine-Immune Axis in Human Rheumatoid Arthritis. Arch Immunol Ther Exp (Warsz) 2000;48:417-427.
43. Templ E, Koeller M, Riedl M, Wagner O, et al. Anterior Pituitary Function in Patients With Newly Diagnosed Rheumatoid Arthritis. Br J Rheumatol 1996;35:350-356.
44. Walton PE, Cronin MJ, Tumor Necrosis Factor-Alpha and Interferon-Gamma Reduce Prolactin Release in Vitro. Am J Physiol 1990;259:E672-E676.